HMO with 32 bedrooms approved at second attempt
The proposed development in Beverley Road, Hull, was resubmitted to the city council having been turned down in March last year.
A senior councillor told the planning committee that the community was "absolutely against" the application, while Humberside Police said it "may well add to the stresses" on the area.
However, Jason Kay, a property manager, argued that the proposal met the council's "own requirements" and would prevent the building being "left to decay".
Councillors heard that the development would incorporate a gym and cinema room. The bedrooms, all with en-suite facilities, would be spread across three floors.
The building had been occupied by Alan Wood & Partners, an engineering consultancy, for the past 40 years.
Mr Kay told the committee that the firm had outgrown the premises and would be looking for a larger site, the Local Democracy Reporting Service said.
He suggested that, should the proposal be turned down, there would be a "significant chance" of jobs losses and of Alan Wood moving out of the city.
Councillor Paul Drake-Davis, the council's portfolio holder for regeneration and housing, said there were too many HMOs in the area and they had a "significant detrimental effect on the local community".
He called on the committee to "show support for the residents".
Councillor David McCobb argued that an "over-proliferation" of HMOs was "having a significant detrimental affect on the local community".
The application, for 337-341 Beverley Road, was narrowly approved by five votes to four, with one abstention.
Speaking after the meeting, Mr Kay said he was "over the moon" with the decision.
Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Plan for multiple occupancy house turned down
Homes could be built on site of Hull shed supplier
Public to help spend £500k on Hull streets
Hull City Council - planning
Local Democracy Reporting Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
6 hours ago
- CNBC
The most powerful passports of 2025: The US and the UK fall, while India rises
Singapore has the world's strongest passport — again, according to the latest Henley Passport Index. The ranking, released Tuesday, shows the small nation-state retaining the top spot in the index, after it broke a six-way tie for the accolade earlier this year. In 2024, Singapore shared the top ranking with Japan, Germany, Italy, Spain and France. The latest ranking shows Japan and South Korea tied for second place, with the other former No. 1 contenders tied for third place with Denmark, Finland and Ireland. The Henley Passport Index is a widely followed ranking of global passports, which assesses passport strength by one metric — the number of destinations holders can visit without needing to obtain a visa. The index ranks countries according to data provided by the International Air Transport Association, it said. The ranking focuses mainly on ease of travel, while another ranking closely monitored by CNBC Travel, the Nomad Passport Index, ranks passports by five criteria, including taxation, and is more focused on global citizenship. Henley's latest ranking shows the U.S. passport slipping to 10th place from United Kingdom's passport also moved down the list, landing in sixth place from fifth, it showed. This represents a continuation of a "long-term downward trend" for the two countries — both of which were once considered the most powerful passports in the world, according to Henley & Partners. "Notably, the U.S. is now on the brink of exiting the Top 10 altogether for the first time in the index's 20-year history," the company said in a statement. The top 10 list shows a ranking mostly dominated by European countries, but led by three key Asian economies: 1 Singapore 2. Japan2. South Korea3. Denmark3. Finland3. France3. Germany3. Ireland3. Italy3. Spain4. Austria 4. Belgium4. Luxembourg4. Netherlands4. Norway4. Portugal4. Sweden5. Greece5. New Zealand5. Switzerland6. United Kingdom7. Australia7. Czechia 7. Hungary7. Malta7. Poland8. Canada8. Estonia8. United Arab Emirates9. Croatia9. Latvia9. Slovakia9. Slovenia10. Iceland10. Lithuania10. United States Singaporeans can access 193 countries without needing a visa, while the countries tied for the 10th spot can access 182, according to the ranking. India's passport jumped the most of any country in the past six months, rising to 77th from 85th, according to Henley & Partners. An analysis of the ranking over the past decade showed the UAE rising 34 places in the ranking, the company said. It is the only "big riser" to break into the top 10 during this time, it said. China also rose 34 spots in the past 10 years, the company said, a move it called "particularly impressive" considering that China doesn't have visa-free access to Europe's Schengen Area. Afghanistan's passport remained in last place on the list, granting visa-free access to just 25 countries worldwide, the company said.
Yahoo
10 hours ago
- Yahoo
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MISSISSAUGA, Ontario, July 22, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. "John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations," said Mike Druhan, MedX President, Dermatology Services. "His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success." "Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism," said John Gevisser. "As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance." While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. "The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time," said Ken McKay, Chairman of the Board.
Yahoo
17 hours ago
- Yahoo
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an 'Outperform' rating and a $5 price target. The research firm remains confident about the company's long-term prospects following its pivot from an antibody discovery platform to one that develops its internal pipeline. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Leerink Partners is especially bullish about the company's upcoming programs ABCL575, an OX40L antagonist targeting atopic dermatitis, and ABCL635, an NK3R antagonist for vasomotor symptoms. The two programs are scheduled to enter Phase 1 clinical trials in the third quarter of 2025. The research firm also pointed out that AbCellera's existing antibody discovery collaborations are well-positioned to deliver long-term value. It expects the company to benefit from milestone payments and royalties as it leverages antibody capabilities towards a pipeline focused on validated targets. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that focuses on discovering and developing antibody-based medicines. It leverages a proprietary, AI-powered technology platform to search, decode, and analyze natural immune systems, identifying antibodies that can be developed into potential drugs. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
